Medtronic (NYSE:MDT) has received FDA 510(k) clearance for its Nellcor pulse oximetry system with the Nell-EQ intelligent ...
A literature search was done for this briefing in accordance with the interim process and methods statement. This briefing includes the most relevant or best available published evidence relating to ...
January 22, 2026 /3BL/ – Medtronic, a global leader in healthcare technology, announced verification study results for its investigational Nellcor™ pulse oximetry with Nell-EQ™ intelligent processor ...
OBJECTIVE: Pulse oximetry is a standard of care for monitoring oxygenation in neonates. Associated with the use of pulse oximetry is the cost of patient sensors, especially if the sensor is designed ...
This regulatory milestone follows news from earlier this year, when the company announced positive verification study results for its Nellcor™ pulse oximetry system with Nell-EQ™ intelligent processor ...
June 8, 2026 /3BL/ – Medtronic, a global leader in healthcare technology, announced FDA 510(k) clearance of its Nellcor™ pulse oximetry system with Nell-EQ™ intelligent processor. The Nell-EQ™ ...
This regulatory milestone follows news from earlier this year, when the company announced positive verification study results for its Nellcor pulse oximetry system with Nell-EQ intelligent processor.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results